CD133+ human umbilical cord blood stem cells enhance angiogenesis in experimental chronic hepatic fibrosis
Autor: | Salwa Hassan, Olfat Hammam, Faten Salah, Ranya Magdy, Soheir S. Mansy, Hanan El Baz, Ahmed Medhat Zaki, Wafaa Mansour, Nagwa Elkhafif, Hoda Yehia |
---|---|
Rok vydání: | 2010 |
Předmět: |
Microbiology (medical)
Pathology medicine.medical_specialty business.industry Angiogenesis CD34 General Medicine Pathology and Forensic Medicine Vascular endothelial growth factor Endothelial stem cell Neovascularization chemistry.chemical_compound Haematopoiesis chemistry Immunology and Allergy Medicine Stem cell medicine.symptom business Hepatic fibrosis |
Zdroj: | APMIS. 119:66-75 |
ISSN: | 0903-4641 |
Popis: | Elkhafif N, El Baz H, Hammam O, Hassan S, Salah F, Mansour W, Mansy S, Yehia H, Zaki A, Magdy R. CD133+ human umbilical cord blood stem cells enhance angiogenesis in experimental chronic hepatic fibrosis. APMIS 2010. The in vivo angiogenic potential of transplanted human umbilical cord blood (UCB) CD133+ stem cells in experimental chronic hepatic fibrosis induced by murine schistosomiasis was studied. Enriched cord blood-derived CD133+ cells were cultured in primary medium for 3 weeks. Twenty-two weeks post-Schistosomiasis infection in mice, after reaching the chronic hepatic fibrotic stage, transplantation of stem cells was performed and mice were sacrificed 3 weeks later. Histopathology and electron microscopy showed an increase in newly formed blood vessels and a decrease in the fibrosis known for this stage of the disease. By immunohistochemical analysis the newly formed blood vessels showed positive expression of the human-specific angiogenic markers CD31, CD34 and von Willebrand factor. Few hepatocyte-like polygonal cells showed positive expression of human vascular endothelial growth factor and inducible nitric oxide synthase. The transplanted CD133+ human stem cells primarily enhanced hepatic angiogenesis and neovascularization and contributed to repair in a paracrine manner by creating a permissive environment that enabled proliferation and survival of damaged cells rather than by direct differentiation to hepatocytes. A dual advantage of CD133+ cell therapy in hepatic disease is suggested based on its capability of hematopoietic and endothelial differentiation. |
Databáze: | OpenAIRE |
Externí odkaz: |